Keisuke et al. combined meso-CAR T cells with oncolytic adenoviruses expressing TNF-α and IL-2, which not only controlled the progression of in situ tumor in PDA mice driven by KRAS mutation, but also inhibited tumor metastasis, showing a strong clinical prospect [136]. Here, KRAS is linked to neoplasm.